Department of Population Sciences, City of Hope, Duarte, CA, USA.
Department of Computational and Quantitative Medicine, City of Hope, CA, USA.
J Natl Cancer Inst. 2020 Nov 1;112(11):1153-1161. doi: 10.1093/jnci/djaa022.
Long-term mortality after hematopoietic cell transplantation (HCT) is conventionally calculated from the time of HCT, ignoring temporal changes in survivors' mortality risks. Conditional survival rates, accounting for time already survived, are relevant for optimal delivery of survivorship care but have not been widely quantified. We estimated conditional survival by elapsed survival time in allogeneic HCT patients and examined cause-specific mortality.
We calculated conditional survival rates and standardized mortality ratio for overall and cause-specific mortality in 4485 patients who underwent HCT for malignant hematologic diseases at a large transplant center during 1976-2014. Statistical tests were two-sided.
The 5-year survival rate from HCT was 48.6%. After surviving 1, 2, 5, 10, and 15 years, the subsequent 5-year survival rates were 71.2%, 78.7%, 87.4%, 93.5%, and 86.2%, respectively. The standardized mortality ratio was 30.3 (95% confidence interval [CI] = 29.2 to 35.5). Although the standardized mortality ratio declined in longer surviving patients, it was still elevated by 3.6-fold in survivors of 15 years or more (95% CI = 3.0 to 4.1). Primary disease accounted for 50% of deaths in the overall cohort and only 10% in 15-year survivors; the leading causes of nondisease-related mortality were subsequent malignancy (26.1%) and cardiopulmonary diseases (20.2%). We also identified the risk factors for nondisease-related mortality in 1- and 5-year survivors.
Survival probability improves the longer patients survive after HCT. However, HCT recipients surviving 15 years or more remain at elevated mortality risk, largely because of health conditions other than their primary disease. Our study findings help inform preventive and interventional strategies to improve long-term outcomes after allogeneic HCT.
造血细胞移植(HCT)后的长期死亡率通常从 HCT 时间开始计算,忽略了幸存者死亡风险的时间变化。考虑到已经存活的时间,条件生存率与生存护理的最佳提供相关,但尚未广泛量化。我们通过异基因 HCT 患者的已存活时间来估计条件生存率,并检查了特定原因的死亡率。
我们计算了 1976 年至 2014 年在一家大型移植中心接受恶性血液疾病 HCT 的 4485 例患者的总体和特定原因死亡率的条件生存率和标准化死亡率比。统计检验为双侧。
HCT 后的 5 年生存率为 48.6%。在存活 1、2、5、10 和 15 年后,随后的 5 年生存率分别为 71.2%、78.7%、87.4%、93.5%和 86.2%。标准化死亡率比为 30.3(95%置信区间[CI] = 29.2 至 35.5)。尽管在存活时间较长的患者中,标准化死亡率比有所下降,但在存活 15 年或更长时间的患者中,仍高出 3.6 倍(95%CI = 3.0 至 4.1)。原发性疾病占总队列死亡人数的 50%,而在 15 年幸存者中仅占 10%;非疾病相关死亡的主要原因是随后的恶性肿瘤(26.1%)和心肺疾病(20.2%)。我们还确定了 1 年和 5 年幸存者中非疾病相关死亡的危险因素。
HCT 后患者存活时间越长,生存概率越高。然而,存活 15 年或更长时间的 HCT 受者仍面临较高的死亡风险,主要是由于原发性疾病以外的健康状况。我们的研究结果有助于为异基因 HCT 后改善长期结果提供预防和干预策略。